House Investigation Of COX-2 Promotional Practices Turns Attention To Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Government Reform Committee members discuss extending their investigation on Vioxx promotional practices to other COX-2 drugs. FDA Office of New Drugs' Jenkins rebukes Merck for avoiding discussion of certain cardiovascular risk data during physician detailing visits before a 2002 Vioxx labeling change.